Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Provinciali, Mauro ^a   Barucca, Alessandra ^a   Orlando, Fiorenza ^a   Pierpaoli, Elisa ^a  

^a INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL; CELLULAR IMMUNITY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PATHOLOGY; PLASMID; SECONDARY IMMUNIZATION; TRANSGENIC MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PLASMIDS; RECEPTOR, ERBB-2;

EID: 85020635079     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-03286-8     Document Type: Article

References (36)

1. Finn, O. J. & Forni, G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14, 172-177 (2002).
2. Quaglino, E. et al. Immunological prevention of spontaneous tumours: a new prospect? Immunol. Lett. 80, 75-79 (2002).
3. Cavallo, F. & Forni, G. Recent advances in cancer immunotherapy with an emphasis on vaccines. Exp. Rev. Vaccines 8, 25-28 (2009).
4. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-82 (1987).
5. Hynes, N. E. & Stern, D. F. The biology of erbB2/neu/HER2 and its role in cancer. BBA 1198, 165-184 (1994).
6. Ross, J. S. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009).
7. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology 495, 61(Suppl 2), 13 (2001).
8. Colombo, M. P. & Forni, G. Cytokine gene transfer in tumour inhibition and tumour therapy: where are we now? Immunol. Today 15, 48-51 (1994).
9. Cavallo, F. et al. Antitumour efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049-1058 (1997).
10. Provinciali, M., Argentati, K. & Tibaldi, A. Efficacy of cancer gene therapy in ageing: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumour specific immune memory in old mice. Gene Ther. 7, 624-632 (2000).
11. Provinciali, M., Smorlesi, A., Donnini, A., Bartozzi, B. & Amici, A. Low effectiveness of DNA vaccination against HER-2/ neu in ageing. Vaccine 21, 843-848 (2003).
12. Lustgarten, J., Dominguez, A. L. & Thoman, M. Aged mice develop protective antitumour immune responses with appropriate costimulation. J. Immunol. 173, 4510-4515 (2004).
13. Provinciali, M. & Smorlesi, A. Immunoprevention and immunotherapy of cancer in aging. Cancer Immunol. Immunother. 54, 93-106 (2005).
14. Sharma, S., Dominguez, A. L. & Lustgarten, J. Aging affect the anti-tumour potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp. Gerontol. 41, 78-84 (2006).
15. Gravekamp, C. The impact of aging on cancer vaccination. Curr. Opin. Immunol. 23, 555-560 (2011).
16. Pfister, G. et al. Naïve T cells in the elderly: are they still there? Ann. N. Y. Acad. Sci. 1067, 152-157 (2006).
17. Muller, W. J., Sin, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-15 (1988).
18. Kang, I. et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J. Immunol. 173, 73-81 (2004).
19. Hainz, U. et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 23, 3232-3235 (2005).
20. Amici, A. et al. DNA vaccination with full-length or truncated Neu induced protective immunity against the development of spontaneous mammary tumours in HER-2/neu transgenic mice. Gene Therapy 7, 703-706 (2000).
21. Lollini, P. L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nat. Rev. Cancer 6, 204-216 (2006).
22. Gravekamp, C. & Jahangir, A. Is cancer vaccination feasible at older age? Exp. Gerontol. 54, 138-144 (2014).
23. Utsuyama, M. et al. Differential age-change in the numbers of CD4+CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood. Mech. Ageing Dev. 63, 57-68 (1992).
24. Smorlesi, A. et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24, 1766-1775 (2006).
25. Provinciali, M. Immunosenescence and cancer vaccines. Cancer Immunol. Immunother. 58, 1959-1967 (2009).
26. Pierpaoli, E. et al. Effect of annatto-tocotrienols supplementation on the development of mammary tumours in HER-2/neu transgenic mice. Carcinogenesis 34, 1352-1360 (2013).
27. Pierpaoli, E. et al. Antiangiogenic and antitumour activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Carcinogenesis 36, 1169-1179 (2015).
28. Quaglino, E. et al. Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. Cancer Res. 64, 2858-2864 (2004).
29. Curcio, C. et al. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 15, 108-114 (2008).
30. Rovero, S. et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165, 5133-5142 (2000).
31. Stein, P. et al. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization. PLoS One 6(11), e27911, doi:10.1371/journal.pone.0027911 (2011).
32. Espinoza Mora, M. R. et al. Depletion of regulatory T cells augments a vaccine-induced T effector cell response against the liverstage of malaria but fails to increase memory. PLoS One 9(8), e104627, doi:10.1371/journal.pone.0104627 (2014).
33. Jagger, A., Shimojima, Y., Goronzy, J. J. & Weyand, C. M. Regulatory T cells and the immune aging process: a mini-review. Gerontology 60, 130-137 (2014).
34. Bueno, V., Sant'Anna, O. A. & Lord, J. M. AGE 36(6), 9729 doi:10.1007/s11357-014-9729-x. (2014).
35. Yan, J. et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumour growth in a syngeneic prophylactic and therapeutic murine model. Cancer gene Ther. 21(12), 507-17, doi:10.1038/ cgt.2014.56. (2014).
36. Donnini, A., Re, F., Orlando, F. & Provinciali, M. Intrinsic and Microenvironmental Defects Are Involved in the Age-Related Changes of Lin-c-kit-Hematopoietic Progenitor Cells. Rejuven. Res 10, 1-14 (2007).